Unexpected, discordant effects of aspirin on platelet reactivity

Farrell, Timothy P.; Hayes, Karen; Tracy, PB; Sobel, Burton E.; Schneider, Dietmar

doi:10.1016/s0735-1097(98)82169-4

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2001

2003

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These patients are aspirin resistant 35,36 . Aspirin resistance may be due to the other factors (besides thromboxane) in the physiologic milieu that activate platelets, or there may be fluctuations in the thrombotic milieu of some patients requiring higher doses to obtain a therapeutic effect 37,38 . Finally, there may be as yet unidentified patient characteristics that render some patients resistant to the effects of aspirin either all or some of the time 39 .…”

Section: Discussionmentioning

confidence: 99%

Effect of different aspirin doses on platelet aggregation in patients with stable coronary artery disease

Malhotra¹,

Sharma²,

Grover³

et al. 2003

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of different aspirin doses on platelet aggregation in patients with stable coronary artery disease

Malhotra¹,

Sharma²,

Grover³

et al. 2003

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

Variable Interindividual Responses to Antiplatelet Therapies – Do They Exist, Can We Measure Them, and Are They Clinically Relevant?

Graaff¹,

Steinhubl²

2001

Heart Drug

View full text Add to dashboard Cite

Many patients suffer thrombotic events such as myocardial infarction, stroke and peripheral embolism despite therapy with recommended doses of all currently approved antiplatelet agents. Researchers have suggested that a subset of patients may be resistant to the antiplatelet effects of aspirin, and have developed substantial evidence to support this theory. The thienopyridines ticlopidine and clopidogrel and the glycoprotein IIb/IIIa inhibitors also exhibit substantial interpatient variability in the level of platelet inhibition they achieve. There are several biochemical factors that may contribute to the etiology of individual resistance to antiplatelet medications. Some studies suggest that the variability in patient responsiveness to these drugs may have clinical consequences, and data from trials evaluating clinical end points are needed to further elucidate this correlation.

show abstract

Unexpected, discordant effects of aspirin on platelet reactivity

Cited by 2 publications

References 0 publications

Effect of different aspirin doses on platelet aggregation in patients with stable coronary artery disease

Effect of different aspirin doses on platelet aggregation in patients with stable coronary artery disease

Variable Interindividual Responses to Antiplatelet Therapies – Do They Exist, Can We Measure Them, and Are They Clinically Relevant?

Contact Info

Product

Resources

About